Dr. Wang-Gillam on PF-04136309 Plus FOLFIRINOX in Pancreatic Adenocarcinoma

Andrea Wang-Gillam, MD, PhD
Published: Saturday, Jan 17, 2015



Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the combination of the CCR2 antagonist PF-04136309 with FOLFIRINOX for the treatment of patients with borderline resectable and locally advanced pancreatic adenocarcinoma.

A phase Ib study investigating the combination found that the toxicity was very comparable with the FOLFIRINOX regimen alone. Efficacy findings were promising, notes Wang-Gilliam. The study found that 48% of patients taking the combination had a partial response and 48% had stable disease.

<<< View more from the 2015 GI Cancer Symposium



Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the combination of the CCR2 antagonist PF-04136309 with FOLFIRINOX for the treatment of patients with borderline resectable and locally advanced pancreatic adenocarcinoma.

A phase Ib study investigating the combination found that the toxicity was very comparable with the FOLFIRINOX regimen alone. Efficacy findings were promising, notes Wang-Gilliam. The study found that 48% of patients taking the combination had a partial response and 48% had stable disease.

<<< View more from the 2015 GI Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x